Fund moves

Abbott Laboratories (ABT): Union Bancaire Privee, UBP SA reduced its stake -30K shares

Union Bancaire Privee, UBP SA reduced its stake in Abbott Laboratories, per its Q2 2025 13F.

220K
Shares reported · -30K vs prior quarter
0.49%
Disclosed portfolio weight
$33.7M
Reported value
Holdings as of
Jun 30, 2025
Filed
Jul 18, 2025

What stands out in this filing

  • 250,622 shares in Q1 2025, 220,421 now (−12.1% in share count).
  • Reported at $33.7M, 0.49% of the portfolio value in this 13F filing.
  • 79 other tracked managers reported the same kind of change for Q2 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  2. May 12, 2025CongressDisclosed sale of ABT — reported range $50,001 - $100,000
  3. Jun 24, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  4. Jul 10, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  5. Jul 18, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000

What came next

  1. Jul 21, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  2. Aug 8, 2025InsiderCFO sold ~$747K of ABT shares in the open market
  3. Aug 14, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  4. Sep 4, 2025FDAFDA device clearance: EnSite™ X EP System, AutoMark Index Software License (ENSITE-AMI-01); EnSite™ X EP System, AutoMark Index Temporary Software License (ENSITE-D-AMI-01)
  5. Sep 10, 2025FDARecall: TactiFlex Sensor Enabled Ablation Catheter, 8F, 115 cm, FJ, (BiD Curve F-J), REF A-TFSE-FJ; cardiac catheter
  6. Sep 10, 2025FDARecall: TactiFlex Sensor Enabled Ablation Catheter, 8F, 115 cm, DD, (BiD Curve D-D), REF A-TFSE-DD; cardiac catheter
  7. Sep 10, 2025FDARecall: TactiFlex Sensor Enabled Ablation Catheter, 8F, 115 cm, D, (UniD Curve D), REF A-TFSE-D; cardiac catheter
  8. Sep 10, 2025FDARecall: TactiFlex Sensor Enabled Ablation Catheter, 8F, 115 cm, F, (UniD Curve F), REF A-TFSE-F; cardiac catheter
  9. Sep 10, 2025FDARecall: TactiFlex Sensor Enabled Ablation Catheter, 8F, 115 cm, DF, (BiD Curve D-F), REF A-TFSE-DF; cardiac catheter
  10. Sep 17, 2025FDAFDA device clearance: Assert-IQ (DM5000); Assert-IQ (DM5300); Assert-IQ (DM5500); Merlin.net (MN7000)
  11. Sep 18, 2025FDARecall: Brand Name: Alinity hq Analyzer Product Name: Alinity hq Analyzer Model/Catalog Number: 09P68-01 Software Version: 5.0 to 5.10.1 for OUS, 5.7 and 5.10.1 in the…
  12. Sep 25, 2025FDAFDA device clearance: Alinity m HCV
  13. Sep 25, 2025FDAFDA device clearance: EnSite™ X EP System
  14. Oct 3, 2025FDAFDA device clearance: Amplatzer Guidewire
  15. Oct 6, 2025FDARecall: Eterna SCS IPG (Implantable Pulse Generator), Model Number 32400
  16. Oct 6, 2025FDARecall: Liberta RC DBS IPG (Implantable Pulse Generator), Model Number 62400
  17. Oct 6, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  18. Oct 15, 2025Company filing · Form 8-K · ResultsReported its results
  19. Oct 29, 2025FDAFDA device clearance: Seguin Annuloplasty Ring
  20. Nov 13, 2025FDARecall: Alinity ci-series System Control Module (SCM), REF: 03R70-01, 03R70-20
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

How this filing works

Explore the data

Common questions

What does this filing report about Abbott Laboratories (ABT) stock?

Union Bancaire Privee, UBP SA reduced its stake in Abbott Laboratories, per its Q2 2025 13F. Now 220K shares, $33.7M reported value, 0.49% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2025. Filed: Jul 18, 2025.

What stands out in this filing?

250,622 shares in Q1 2025, 220,421 now (−12.1% in share count). Reported at $33.7M, 0.49% of the portfolio value in this 13F filing. 79 other tracked managers reported the same kind of change for Q2 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Abbott Laboratories recently?

For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.

Does this mean ABT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data